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Memory decline evolves independently of disease activity
in MS
B Duque, J Sepulcre, B Bejarano, L Samaranch, P Pastor and P Villoslada
Background The natural history of cognitive impairment in multiple sclerosis (MS) and its relation-
ship with disease activity is not well known. In this study, we evaluate a prospective cohort of 44
MS patients who were followed every 3 months for 2 years. Cognitive evaluation was done at base-
line and by the end of the study using the Brief Repeatable Battery-Neuropsychology. Clinical evalu-
ation included assessment of new relapses and changes in disability (Extended Disability Status Scale
(EDSS)) confirmed at 6 months.
Results We found that verbal memory performance deteriorates after 2 years in patients with MS.
These changes were observed in stable and active patients both in terms of relapses and disability
progression, even at the beginning of the disease, and in patients with or without cognitive
impairment at study entry. Attention and executive functions measured with the symbol digit
modality test (SDMT) declined after 2 years in patients with confirmed disability progression. Fur-
thermore, SDMT performance correlated with the EDSS change.
Conclusions Our findings indicate that verbal memory steadily declines in patients with MS from
the beginning of the disease and independently of other parameters of disease activity. Multiple
Sclerosis 2008; 14: 947–953. http://msj.sagepub.com
Key words: brief repeatable battery-neuropsychology; cognitive impairment; longitudinal study;
multiple sclerosis; selective reminding test; symbol digit modality test
Introduction
Cognitive impairment is frequent in patients with
multiple sclerosis (MS), affecting up to 60% of
cases, and it is present even at the beginning of
the disease. Information processing speed is com-
monly affected, and the cognitive domains more
often affected are memory, attention, and executive
functions [1,2]. Although cognitive abnormalities
in MS are not easily detected without appropriate
neuropsychological batteries, they are frequently
identified correctly by patients and might cause sig-
nificant functional impairment in patient’s daily
activities. Indeed, their impact in daily life, in addi-
tion to physical disability and behavioral changes,
might explain why up to 70% of patients after a
long disease duration are unemployed, divorced,
and socially isolated [3,4].
The natural history of cognitive impairment in
patients with MS is still not well known. For exam-
ple, whether cognitive abnormalities correlate with
disease progression or if the pattern of such dys-
function differs between disease subtypes is still a
matter of discussion [5–8]. Moreover, we still do
not know in detail how cognitive functions decline
with the disease, and what the relationship is with
Magnetic Resonance Imaging (MRI) and neurophys-
iology measurements [8]. The unraveling of the nat-
ural history of cognitive impairment in MS will
improve our understanding of which patients will
benefit from therapeutic interventions such as cog-
nitive therapy [9] or new cognitive enhancing drugs
[10,11] will develop specific social support programs
for coping with such impairment.
The aim of our study was to study the changes in
cognitive performance during a 2-year observation
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period in a cohort of patients at the early to
medium phase of their disease. We were interested
in identifying the most sensitive cognitive domains




We studied 44 patients with MS and 25 healthy
controls. Patients were recruited consecutively in
the MS center of a referral hospital from April
2004 to May 2005. Controls were matched by sex,
age, and educational level with the patient group,
and they were used for controlling for practice
effect of neuropsychological test (but not for
obtaining normative values, which have been pre-
viously published [2]). All subjects gave their
informed consent, and the local Ethics Committee
approved the study. Inclusion criteria were 1) hav-
ing MS [12]; 2) suffering from the disease for less
than 10 years and Extended Disability Status Scale
(EDSS) < 6.0; 3) any disease subtype; 4) no history
of psychiatric or neurological disease (other than
MS) or any other major medical illness were
included, and no history of alcohol or drug abuse
that could interfere with neuropsychological perfor-
mance; 5) being right-handed (>70% Oldfield scale
[13]) native Spanish speakers. The use of immuno-
modulatory therapies for MS was allowed. Exclusion
criteria were 1) presence of visual, motor (dominant
hand), or auditory deficits that prevent the comple-
tion of the tests; 2) having suffered a relapse within
the past 3 months; 3) presence of psychiatric disor-
ders identified with the Cummings’ Neuropsychia-
try Inventory [14], the Hamilton’s Depression Rat-
ing Scale [15] (≥8 points), the Hamilton’s Anxiety
Rating Scale [16] (≥6 points). No subjects were suf-
fering clinical relapse at the time of the neuropsy-
chological assessment at baseline and endpoint of
the study. We screened 61 patients recruited for
a study for determining the diagnostic accuracy of
retinal abnormalities in predicting disease activity
in MS [17]. Of them, 44 patients were included in
the study (Table 1). After 2 years, we were able to
reassess with the neuropsychology battery in 39
patients (Table 1). Five patients dropped out of
the study (3 clinically isolated syndrome and 2
relapsing-remitting patients): one was discarded
immediately after study inclusion because of
the presence of active isquemic cardiopathy and
another four because they changed their residency
by the middle of the follow-up (n = 2) or declined to
perform a second cognitive evaluation (n = 2). The
clinical characteristics of dropped-out patients did
not differ from the overall cohort.
Clinical evaluation
Patients were clinically followed every 3 months for
2 years and we recorded presence of new relapses
and change in disability. The clinical characteristics
of this cohort are described in detail elsewhere [17].
Physical disability was evaluated in every visit using
the EDSS [18] and the Multiple Sclerosis Functional
Composite (MSFC) [19]. Disability progression was
defined as an increase in 1 point in the EDSS (0.5
point in patients with EDSS > 5.5) confirmed in a
second visit 6 months apart [20]. Finally, we
assessed the homogeneity between active and stable
patients (patients with or without disability progres-
sion and patients with or without relapses) to avoid
potential confounders within the sample, such as
different baseline patterns of cognitive impairment,
EDSS, MSFC, or disease duration. Both groups did
not statistically differ in those baseline variables
(P > 0.05 in all cases).
Cognitive performance assessment
Neuropsychological performance was assessed
using the validated Spanish version of the Brief
Repeatable Battery-Neuropsychological (BRB-N).
Table 1 Clinical information of patients with MS at baseline and by the end of the study (2-year follow-up)
MS baseline (n = 44) MS follow-up (n = 39) HC (n = 25) P
Age (years)a 36 ± 9.43 37.95 ± 9.84 39 ± 13.9 ns
Sex ratio (M/F) 14/30 12/27 7/16 ns
Education (years)b 14 (7 to 28) 14 (7 to 28) 13 (7 to 29) ns
MS subtype 15CIS/21RR/4SP/4PP 6CIS/22RR/7SP/4PP — —
Disease duration (years)b 6.25 (1 to 36) 7 (3 to 38) — —
EDSS scoreb 2 (0 to 7.0) 2.5 (0 to 8.0) — —
MSCF scoreb 0.25 (−1.81 to 1.08) 0.37 (−5.66 to 1.27) — —
MS, multiple sclerosis; ns, no significant differences between healthy control (HC) and MS at baseline; CIS, clinically isolated syn-
drome; RR, relapsing-remitting; SP, secondary progressive; PP, primary progressive; EDSS, Expanded Disability Status Scale; MSFC,
MS Functional Composite. Data are expressed in mean ± standard deviationa or median (range)b depending on the parametric or
non-parametric distribution of the variable.
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Normative values in our population have been
obtained previously in a cohort of 150 healthy indi-
viduals [2]. Neuropsychological evaluation was car-
ried out by a single trained neuropsychologist (BD).
The BRB-N was administered twice (baseline and
by the end of the study) using a Spanish parallel
version (for all subtests, except for verbal fluency
tests because in this case it is not applicable) to min-
imize possible learning effects swing to repeated
exposure. The BRB-N included 1) Bushke Selective
Reminding test (SRT); 2) 10/36 Spatial Recall Test
(SPART); 3) Symbol Digit Modalities Test (SDMT);
4) Paced Auditory Serial Addition Task at 3 s
(PASAT 3); and 5) Word list generation (WLG).
PASAT was saturated between baseline and end of
the study by the administration of the MSFC scale
every 3 months. We assessed the inter-rater reliabil-
ity between two researchers (JS and BD) using 20
randomly selected patients. Intraclass coefficient
for the BRB-N tests were high in all cases and varied
from 0.703 (P = 0.003) to 0.972 (P < 0.001). None of
the individuals had previously been subjected to
these tests and no one refused to perform them.
We defined presence of cognitive impairment if
they obtained abnormal results in the BRB-N lower
than 1.5 SD using the normative cut-off values, in
at least two tests. We also calculated the BRB-N-Z
score, as described previously [2].
ApoE genotyping
Fluorogenic allele-specific TaqMan probes and pri-
mers were used for ApoE isoforms genotyping as
described [21]. Five samples previously genotyped
in our laboratory by restriction fragment length
polymorphism analysis (Hha1 restriction enzyme)
were included in the TaqMan experiments as inter-
nal controls. Final step analysis was performed in an
ABI7300 Real-Time PCR Systems (Applied Biosys-
tems, Foster City, California, USA). Allele calling
was carried out using the allelic discrimination anal-
ysis module of the ABI Sequence Detection Software
(Applied Biosystems, Foster City, California, USA).
Statistical analysis
The normal distribution of the variables was
assessed with the Kolmogorov-Smirnof test. Demo-
graphic variables were compared between MS and
healthy control groups using t-test or X2 when
appropriate. We used the paired t-test for compar-
ing normally distributed variables and the Wil-
coxon test for non-parametric ones. Correlation
between the BRB-N tests and the patient’s disability
changes were assessed by using the Pearson or
Spearman correlation test. Level of significance
was set at P < 0.05. Statistical analyses were per-
formed using SPSS 13.0 (SPSS Inc. Chicago, Illinois,
USA).
Results
Clinical characteristics of the patient’s cohort
During the follow-up period, 20 patients were
relapse-free, and the disease course changed from
clinically isolated syndrome (CIS) to relapsing-
remitting multiple sclerosis (RRMS) in six patients
and from RRMS to SPMS in three patients. Relapse
rate along follow-up period was 1.15. The increase
in the EDSS at the end of the study for the overall
cohort was 0.35 ± 0.69, and 11 patients had disabil-
ity progression confirmed at 6 months.
Longitudinal changes in cognitive performance and
disease activity
We found a decrease in the scores of verbal memory
tests after the 2-year follow-up (Table 2), mainly in
storage and retrieval. The decrease in the verbal
memory performance after 2 years was present in
both relapse-free and non-relapse-free patients, in
patients with or without disability progression,
and in patients with or without cognitive
impairment at baseline (Figure 1). Thus, we found
a decrease in verbal memory performance that was
not associated with the presence of relapses,
increase in physical disability, or previous cognitive
impairment. Because the sample size of patients
with progressive forms of MS was small, we did
not perform comparisons between disease subtypes.
However, we found that CIS patients that converted
to RRMS have a tendency for a decrease in the ver-
bal memory storage score (P = 0.06) compared with
the ones that were not converted (P = 0.21). More-
over, we found that patients with disability progres-
sion during the follow-up but not stable patients
have a decline in the SDMT performance
(P = 0.024). Indeed, we found that the SDMT score
by the end of the study correlated with changes in
EDSS during the follow-up period (r = −0.459;
P = 0.003).
Changes in the prevalence of cognitive impairment
after two years
To define the changes in the prevalence of cogni-
tive dysfunction in patients with MS with disease
evolution, we divided the patients in two sub-
groups based on the number of tests failed at
baseline: unimpaired (<2 subtest below 1.5 SD of
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the normative data) and impaired group (more than
two subtest with a performance <1.5 SD than the
normative data) [2]. The prevalence of memory dys-
function (one subtest below 1.5 SD normative data)
increased from 31% to 41% over the 2-year follow-
up, and the prevalence of cognitive impairment
(two or more subtests below 1.5 SD of the norma-
tive data) rose from 29% to 48%.
We assessed whether a unified measurement of
the cognitive impairment, such as the BRB-N-Z
score [2], is sensitive to detect changes along time
in a 2-year observation period. We found no differ-
ences between BRB-N-Z scores between baseline and
by the end of the study, neither considering the
whole cohort nor when analyzing different sub-
groups (e.g., patients with or without cognitive
impairment, relapses, or disability progression).
Finally, we assessed the influence of genetic mar-
kers and cognitive decline in patients with MS, such
as the ApoE4 genotype because it is associated with
the presence of cognitive impairment in MS [22]. In
our cohort, eight patients were ApoE4 positive
(including two homozygous individuals) and 28
were ApoE4 negative. We found no association
between the ApoE4 genotype and the degree of cog-
nitive impairment (data not shown). However,
because of the small sample size of ApoE4 indivi-
duals, especially for the presence of ApoE4 homozy-
gous, we might lack enough power to detect any
association.
Discussion
In this prospective study, we found that, in a 2-year
period, verbal memory declines in a significant pro-
portion of patients. Our results are in agreement
with the previous findings that verbal memory, in
addition to information processing speed, is the
most frequently affected cognitive domain in MS
[1,8] and indicates that such impairment evolves
over short period of time, starting at the beginning
of the disease and independently of other para-
meters of disease activity such as clinical relapses
and disability accumulation. Moreover, the variable
distribution of MS lesions and the presence of corti-
cal damage [23,24] might explain the independence
between verbal memory deterioration and clinical
relapses. All together, our results suggest that assess-
ment of verbal memory in MS can be useful, in
addition with the evaluation of physical disability,
for identifying disease activity. However, we cannot
exclude that different ways for measuring disease
activity, longer follow-up, or the use of more sensi-
tive methods such as MRI, might identify a relation-
ship between cognitive impairment and disease
activity. The differential onset and decline of cogni-
tive and physical disability might be due to the fact
that cognition depends on widespread brain net-
works that are more sensitive to gray matter atro-
phy and long-tracts disconnection, a process that
also starts and progresses steadily from the begin-
ning of the disease [25,26].
A degree of controversy exists on the correlation
between cognitive impairment and the degree of
physical disability measured with the EDSS scale
[5,27–30]. We found that SDMT decline was associ-
ated with the progression of physical disability. This
result is in agreement with our previous results
showing that SDMT correlates with physical disabil-
ity measured with the EDSS [2]. Because of its mul-
tifactor nature, the SDMT performance is highly
dependent of the integrity of several brain net-
works. For this reason, the impairment in SDMT
performance might reflect a more widespread
brain damage, explaining the partial correlation
with physical disability deterioration or with the
progressive phase [27,31,32]. Indeed, higher EDSS
and progressive course are associated with worse
Table 2 Mean scores of BRB-N battery in controls and patients with MS at baseline and follow-up
BRB-N MS Controls
Baseline Follow-up P Baseline Follow-up P
SRT-S 49.93 ± 11.27 44.51 ± 12.19 <0.001 52.61 ± 12.74 53.65 ± 9.79 ns
SRT-R 39.95 ± 12.94 33.1 ± 15.3 <0.001 45.13 ± 13.51 44.91 ± 13.2 ns
SRT-D 9.11 ± 2.33 8.38 ± 2.38 0.021 10.3 ± 1.46 10.17 ± 1.77 ns
SPART 19.41 ± 4.87 19.77 ± 5.62 ns 22.96 ± 5.62 21.57 ± 6.61 ns
SPART-D 7.36 ± 1.94 6.95 ± 2.35 ns 8.39 ± 2.16 9.09 ± 3.11 ns
SDMT 51.68 ± 14.31 50.31 ± 15.73 ns 51.78 ± 16.15 51.52 ± 17.38 ns
WGLS 27.7 ± 5.65 27.79 ± 8.26 ns 29.17 ± 9.61 28.83 ± 7.77 ns
WGLP 21.0 ± 6.73 21.59 ± 7.57 ns 21.37 ± 6.59 21.64 ± 6.48 ns
PASAT3 49.95 ± 11.6 49.16 ± 11.69 ns 42.65 ± 11.19 45.35 ± 13.44 ns
BRB-N, Brief Repeatable Battery-Neuropsychological; MS, multiple sclerosis; SRT-S, Selective Reminding Test Long-Term Storage;
ns, not significant; SRT-R, Selective Reminding Test Long-Term Retrieval; SRT-D, Selective Reminding Test Delayed Recall; SPART,
10/36 Spatial Recall Test; SPART-D, 10/36 Spatial Recall Test Delayed; SDMT, Symbol Digit Modality Test; WLGS, Word List Genera-
tion Semantic; WLGP, Word List Generation Phonetic; PASAT3, paced auditory serial addition task at 3 seconds interval. The data
were expressed in mean ± standard deviation.
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Figure 1 Association between verbal memory performance, clinical relapses, disability progression, and previous cognitive
impairment in patients with multiple sclerosis. We observed significant decrease in the 3 scores of verbal of the Selective
Reminding Test (SRT), storage (A), retrieval (B), and delayed recall (C), between baseline (white bar) and 2-year follow-up
(gray bar). Patients with relapses have a decrease in the SRT scores (SRT-S: P = 0.003; SRT-R: P = 0.005) and patients without
relapses (SRT-S: P = 0.007; SRT-R: P = 0.004; SRT-D: P = 0.046). D) Clinically isolated syndrome patients converting to RRMS
during follow-up have a trend for impaired SRT-S performance (P = 0.06). Patients with physical disability progression
(decrease in the Expanded Disability Status Scale confirmed at 6 months) during the follow-up have an impaired performance
in the SRT-S (P = 0.05) and SRT-R (P = 0.012). Patients without disability progression also have a decrease in the SRT-R
(P = 0.004) and SRT-D (P = 0.047) by the end of the study. Patients with cognitive impairment by the time of the study entry
have a decrease in the performance of SRT-S (P = 0.005), SRT-R (P = 0.001) and patients without cognitive impairment at
baseline (SRT-S: P = 0.001; SRT-R: P = 0.019).
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cognitive outcome, indicating that although physi-
cal and cognitive impairment may evolve indepen-
dently, they tended to converge in the long-term
[8].
Several studies have found that attention and
spatial or verbal memory deteriorates with disease
duration [7,30,33,34]. Similar to our findings,
other studies found that cognitive deterioration in
patients with MS raises from 20–30% to close to
50% in a similar period of time [7,28,35,36]. How-
ever, some other studies did not confirm such cog-
nitive deterioration rates [8,37–39], which may be
related to the small sample size used or patient
loss during follow-up. Nevertheless, the overall evi-
dence indicates a progressive cognitive decline over
time in a big proportion of patients with MS and
also suggests that the profile of cognitive deficits
tends to extend to cognitive domains previously
preserved [8].
Several methodological limitations might diffi-
cult the interpretation of our findings. Our study,
although it was hospital-based, included consecu-
tive patients to control for population bias. The
sample size was big enough for being able to detect
differences previously described and to identify pro-
gressive decline in verbal memory and was similar
to previous well-controlled studies [7,28,35],
although it was small for confirming the influence
of ApoE4 in cognition. Our results should not be
interpreted as a lack of effect of ApoE4 in cognitive
deterioration, but a suggestion that the magnitude
of its effect is not very high. Although 2-year
follow-up might be a short period compared with
the time over which MS evolves, such a period is
the most used for identifying clinical and biological
markers or testing new therapies. Thus, our results
will be informative in this context and might be
helpful for the design of new clinical studies. We
controlled for mood and psychiatric disorders as
well for the use of psychoactive drugs that might
interfere with neuropsychiatry evaluation. More-
over, the drop-out rate in our study was small and
none of them related to disease progression. In our
study, practice effects were controlled by the use of
alternative versions and by saturating some tests
such as PASAT. Finally, because the pathogenic
basis of disease progression may vary between dif-
ferent disease subtypes, it is possible that the rate of
cognitive deterioration may vary based in the
underlying mechanism of brain damage.
Based on our study and previous studies, we pro-
posed assessing verbal memory (SRT storage and
retrieval) and SDMT for monitoring cognitive dete-
rioration in patients with MS, when more compre-
hensive batteries cannot be administered or for a
quick evaluation in clinical practice or during the
conduction of clinical trials. Verbal memory seems
to be the more sensitive cognitive function for iden-
tifying disease activity and attention, and executive
functions, assessed with SDMT, might be more spe-
cific for detecting tissue damage as suggested by its
correlation with physical disability. Finally, inte-
grated scores such as the BRB-N-Z score seem to
lose sensitivity to detect changes. Longer prospec-
tive studies are required to improve our knowledge
about the natural history of cognitive impairment
in MS.
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